Kaléo

Kaléo is a privately held, commercial-stage biotech company specializing in advanced drug-delivery technology, primarily through its proprietary Aerio™ Auto-Injector Platform. The company has a dual focus: partnering with pharmaceutical companies and government agencies to develop custom drug-device combinations, and commercializing its own portfolio of marketed auto-injector products for anaphylaxis and opioid overdose. With a strong foundation in human factors engineering and automated manufacturing, Kaléo is positioned as a trusted partner in the emergency medicine and medical countermeasures sectors, driven by a patient-first philosophy inherited from its founders.

Aerio™ Auto-Injector Platform: A flexible, adaptable platform for auto-injector design featuring Human Factors Engineering, ~155 issued/pending patents, and fully automated manufacturing for precision and reliability across multiple drug formulations and use cases.

Kaléo competes with large pharmaceutical companies (e.g., Viatris/formerly Mylan with EpiPen) in the epinephrine auto-injector market and with other device companies (e.g., Ypsomed, SHL Medical) in the partnered auto-injector space. Its focus on human factors, voice guidance, and medical countermeasures provides distinct niches, but it faces pressure from generics and well-capitalized rivals.